We used a novel 2-paramenter pharmacokinetic modeling framework that allows biosignatures to be extracted from dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) studies that contain 3-6 timepoints spaced 60-90 seconds apart. These parameters, referred to as P1 and P2, represent leakiness from vessels into the extravascular space and vice versa.
Development of a Novel Imaging Biomarker to Ascertain Responsiveness to Immunotherapy
Currently, a lack of tests to differentiate patients likely to respond to IO vs. poor responders precludes a tailored approach to immunotherapy. Here we describe an imaging biomarker that allows physicians to target breast cancer patients with the highest likelihood of response to immunotherapies.
A 3D Visualization and Prediction Device for Breast Cancer Surgeons and their Patients
Despite chemotherapeutic advances, surgery remains a putative treatment modality for breast cancer. The type of surgery chosen, and its ultimate clinical and cosmetic consequences, depends on a surgeon’s ability to accurately assess a tumor’s size, distribution, and position in the breast relative to anatomical landmarks.
A 3D Visualization Method for Breast Cancer Surgeons and Patients
In order to accurately evaluate the potential success of various surgical options, a surgeon must mentally translate these 2D images into more realistic, 3D image to visualize breast and tumor morphologies.
Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial
We developed the TumorScope engine, a software platform that utilizes pretreatment diagnostic data to build a computational tumor model that simulates in vivo tumor characteristics and interactions, incorporating morphology, metabolism, vascularity, and nutrient and drug delivery.
pCR Score: A Novel Prognostic Method to Estimate the Predictive Probability of pCR in Early-Stage Breast Cancer Patients.
To drive further utility, we now investigate a pCR score as a continuous outcome (0-100) to establish a prognostic system that evaluates the predictive probability that a patient will achieve pCR with any SOC NAT regimen.